Mendel Goldfinger, MD

Mendel Goldfinger, MD, is the clinical program director of hematologic malignancies at Montefiore Einstein Comprehensive Cancer Center and associate professor of oncology and of medicine at Albert Einstein College of Medicine in New York, New York.

Articles by Mendel Goldfinger, MD

TP53-Mutated Myeloid Malignancies | Image Credit: Oleksandr - stock.adobe.com

Less Is More: Advancing Care in TP53-Mutated Myeloid Malignancies

ByMendel Goldfinger, MD

April 14th 2026

Metronomic treatment approaches could represent therapeutic avenues for patients with TP53-mutated myeloid malignancies.

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

ByMendel Goldfinger, MD,Nishi Shah, MD,Dennis L. Cooper, MD

March 22nd 2023

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Latest Updated Articles

Less Is More: Advancing Care in TP53-Mutated Myeloid Malignancies
April 14th 2026
CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability
March 22nd 2023

Mendel Goldfinger, MD

Articles by Mendel Goldfinger, MD

Less Is More: Advancing Care in TP53-Mutated Myeloid Malignancies

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

Latest Updated Articles

Trending on OncLive

TP53 Status and Time Toxicity Shape Sequencing Decisions in EGFR-Mutated NSCLC

Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 NSCLC Trial

Savolitinib Gains NMPA Approval for MET-Amplified Gastric and GEJ Adenocarcinoma

Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma

Rusfertide Maintains Long-Term Thromboembolism Control in Phlebotomy-Dependent Polycythemia Vera